This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Clinical Development Disease Immune Response 
Drug Target Review
JULY 17, 2024
GigaGen’s single-cell recombinant technology enables the selection and replication of a highly specific and diverse antibody response, which can also be modified to create therapeutics that are more potent than those provided by a natural immune response.
The Pharma Data
NOVEMBER 30, 2020
Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease.
Drug Target Review
JULY 11, 2023
In the quest to combat and eradicate diseases, scientists and researchers are increasingly turning to the immense potential of artificial intelligence (AI) as a tool. Her focus initially consisted of preclinical development strategies , clinical development optimisation, target discovery and validation.
75 
SugarCone Biotech
JUNE 10, 2024
[link] Immunity is complex and can be dangerous when exploited clinically, as demonstrated by the lethal administration of TNF, or anti-CD40L antibody (Biogen) or CAR-T cells expressing the CD16 Fc-receptor (Unum), among many other examples. This is the T cell type most closely associated with anti-tumor immune responses.
Drug Target Review
OCTOBER 10, 2024
What are the risks of over-reliance on healthy donor material in early-stage research, and how can decision-makers ensure a balanced integration of diseased material to avoid potential gaps when transitioning to clinical trials? This can lead to low cell yields, poor product quality, and process variability.
52 
Drug Target Review
DECEMBER 28, 2023
These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response. Neoantigens are recognised as non-self and trigger an immune response. Patients with high numbers of clonal neoantigens show improved disease-free survival.
105 
Drug Target Review
DECEMBER 27, 2023
This interaction inhibits inflammation and immune activation, and in particular prevents macrophages from phagocytosing and destroying cancer cells. By blocking CD24 with an antibody drug, our goal is to powerfully reactivate the anti-cancer immune response and drive therapeutic efficacy.
105 
Drug Target Review
DECEMBER 13, 2023
Combinatorial analytics approaches identify combinations of features that together are associated with the disease phenotype in patient sub-groups, capturing the non-linear effects of interactions between multiple genes. The combinatorial approach is considerably more sensitive than GWAS and requires much smaller patient populations.
145 
Drug Target Review
JUNE 9, 2023
This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.
105 
The Pharma Data
JUNE 2, 2022
Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. pneumoniae invasive disease and pneumonia in adults 50 years and above.
52 
The Pharma Data
DECEMBER 15, 2020
A healthy immune system defends the body against disease and other conditions. However, if the immune system malfunctions, it can attack healthy cells, tissues and organs. Autoimmune disease impacts different parts of the body, weakening functionality. Autoimmune diseases affect more than 24 million people in the U.S.
52 
The Pharma Data
MAY 31, 2022
Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. pneumoniae invasive disease and pneumonia in adults 50 years and above. Pneumococcal disease.
52 
Broad Institute
OCTOBER 11, 2023
He also read everything he could about her disease, including emerging evidence that suggested that the immune system could recognize and kill Merkel cell carcinoma. His mother had a presentation of the disease that suggested her immune system was already on the job.
137 
The Pharma Data
DECEMBER 3, 2020
Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. Based on the positive Phase 1 results reported and the unprecedented need for COVID-19 vaccines, Clover and its partners are confident to enter late-stage clinical development for both adjuvanted vaccines.
52 
Creative Biolabs
JULY 12, 2020
They are currently working with Boehringer Ingelheim to further identify and develop these antibodies. They are expected to enter clinical development later this year. ” The researchers studied the SARS-CoV-2 antibody response of 12 people who recovered from COVID-19. .”
The Pharma Data
MAY 15, 2023
The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. About XinThera XinThera is a private biotechnology company whose mission is to develop best-in-class small molecule drugs to treat cancer and immunologic diseases.
The Pharma Data
JANUARY 12, 2021
Ben-Moshe told BioSpace that BND-22 differs from traditional immunotherapy in that it can elicit a more total immune response. . “It It is a new immune checkpoint that is expressed on three different immune cells: Macrophages, [Natural Killer] NK cells, and T cells. [It]
The Pharma Data
FEBRUARY 22, 2021
(Nasdaq: RIGL) today announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel’s R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. vice president of immunology at Lilly.
The Pharma Data
SEPTEMBER 29, 2020
from Australian investors to progress the INNA-051 clinical development programme. By boosting the natural immune response of the ferrets with our treatment, we’ve seen a rapid eradication of the virus,” said Christophe Demaison, managing director of Ena Respiratory. “If So far, Ena has raised AU$11.7m
The Pharma Data
DECEMBER 13, 2020
SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response. Synlogic’s President and Chief Executive Officer.
The Pharma Data
MARCH 11, 2021
Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The joint development team is working on improving the temperature stability of the mRNA vaccine candidate and targeting a -20°C storage temperature for late-stage clinical trials and at launch.
The Pharma Data
JUNE 25, 2021
In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. About CVnCoV.
52 
The Pharma Data
NOVEMBER 10, 2020
P otential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease. Crohn’s Disease Therapeutics Market Size $4.7 Phase1b/2 clinical study to be conducted in the United States and several European countries. Billion by 2025. and Europe.
The Pharma Data
SEPTEMBER 25, 2020
Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Interim analysis from Phase 1/2a First-in-Human trial supports further clinical development of investigational vaccine candidate JNJ-78436735 (also known as Ad26.COV2.S). Immune Response Data.
The Pharma Data
JUNE 26, 2021
BNT111 is the lead product candidate from BioNTech’s FixVac platform that targets a fixed combination of mRNA-encoded, tumor-associated antigens with the objective of triggering a strong and precise immune response against cancer and is fully owned by BioNTech. The first patient has been dosed in the EU. About FixVac.
PerkinElmer
JANUARY 25, 2023
Confronting and containing the spread of other infectious diseases like tuberculosis, influenza A and B as well as respiratory syncytial virus (RSV) also remained top global health priorities, as was testing to prevent the transmission of sexually transmitted infections, tickborne diseases and more.
52 
Drug Target Review
JANUARY 15, 2024
As T cells develop, chromosomal DNA encoding the TCR of the CD8 T cells of each individual is rearranged and ‘educated’ to respond only to peptides presented in the context of a specific HLA Class I molecule present in that individual. Many potential candidate antigens are under consideration. Engineering soluble T-cell receptors for therapy.
110 
Drug Target Review
APRIL 3, 2024
Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences. Everything started in school with an experiment on isolating DNA from bananas.
105 
The Pharma Data
OCTOBER 25, 2020
We are advancing the clinical development of mRNA-1273 with our Phase 3 COVE study, which is now fully enrolled with a representative demography of participants across ages, ethnicities and high-risk populations. Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co.,
52 The Pharma Data
JANUARY 3, 2021
We are very honored to have someone of Dr. Zeldis’ caliber lead our scientific research and clinical development teams. It is my privilege to advise NexImmune as it seeks to develop novel treatments for melanoma and other cancers,” stated Dr. Weber. . GAITHERSBURG, Md., GAITHERSBURG, Md.,
The Pharma Data
OCTOBER 27, 2020
The company’s lead program is aimed at Friedrich’s Ataxia, a rare inherited genetic disease that causes cardiac and central nervous system dysfunction. AavantiBio has a unique opportunity to change the lives of those living with FA and other rare diseases,” Cumbo said. and China. said of B cells’ potential. “We
The Pharma Data
JANUARY 21, 2021
Its core therapeutic areas are immuno-oncology, autoimmune disorders, and infectious diseases. RRP is a rare, difficult-to-treat and sometimes fatal disease of the upper and lower respiratory tracts. The National Institutes of Health (NIH) is planning on taking over manufacturing and clinical development.
The Pharma Data
JANUARY 31, 2021
Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. These findings give confidence that Clover’s COVID-19 vaccine candidates are suitable for further clinical development.”
The Pharma Data
NOVEMBER 9, 2020
(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant.
52 
The Pharma Data
OCTOBER 9, 2021
“While we did not achieve proof of concept in this study, we are committed to advancing our deucravacitinib clinical program in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, as well as in psoriatic arthritis, lupus and other immune-mediated diseases. About Ulcerative Colitis.
52 
The Pharma Data
AUGUST 17, 2021
In the Opdivo plus Yervoy arm, patients received treatment with Opdivo 3 mg/kg every 2 weeks and Yervoy 1 mg/kg every 6 weeks up to 24 months or until disease progression or unacceptable toxicity. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.
52 
The Pharma Data
OCTOBER 21, 2020
Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the U.S. The active IND enables the Company to initiate the first-in-human clinical trial to assess safety and efficacy of ADI-001 in NHL patients. MENLO PARK, Calif.
40 
The Pharma Data
NOVEMBER 12, 2020
The CALAVI trials were launched based on preclinical and early clinical evidence that Calquence could decrease the hyperinflammatory immune response and improve clinical outcomes in patients hospitalised with respiratory symptoms of COVID-19.1 The data will be presented in due course.
52 
The Pharma Data
JANUARY 17, 2021
LONDON–( BUSINESS WIRE )– Ixaka Ltd , an integrated cell and gene therapy company focused on the natural power of the body to cure disease, launches today. The new business will continue to develop Ixaka’s proprietary technologies – concentrated multi-cell therapies (MCTs) and targeted nanoparticle (TNP) therapeutics.
40 
The Pharma Data
MARCH 29, 2022
Spinner, MD, Consulting Physician Infectious Diseases and Pandemic Officer at the University Hospital Rechts der Isar and adjunct teaching professor at the Technical University of Munich, Munich, Germany, said: “Increasing COVID-19 cases, driven by the highly-transmissible BA.2 1-3 Evusheld was generally well-tolerated in the trial.
52 
The Pharma Data
APRIL 9, 2021
The results for these Opdivo -based combinations represent a significant advancement for patients with esophageal cancer who are often diagnosed after their disease has spread and would benefit from new therapeutic options,” said Ian M. development lead, gastrointestinal cancers, Bristol Myers Squibb. Waxman, M.D., About Opdivo.
The Pharma Data
MARCH 29, 2022
“Lung cancer is the leading cause of cancer deaths globally, and unfortunately cases caught in earlier stages continue to contribute to this statistic, with up to 55% of patients who undergo surgery ultimately relapsing and dying of their disease,” said Abderrahim Oukessou, M.D., About Opdivo.
52 
The Pharma Data
JANUARY 3, 2021
Preclinical data from our laboratory have shown that the nasal administration of anti-CD3 stimulates Tregs that can suppress inflammation and ameliorate inflammatory diseases. Furthermore, nasal anti-CD3 dampens cytotoxic CD8 T cell responses that are known to cause lung damage in COVID-19 patients.”. . NEW YORK and LONDON, Jan.
The Pharma Data
NOVEMBER 1, 2020
Highly innovative first-in-class study for treating COVID-19 disease with nasally administered drug. Clinical Data Expected by End of Year. Furthermore, nasal anti-CD3 dampens cytotoxic CD8 T cell responses shown to cause lung damage in COVID-19. NEW YORK and LONDON, Nov.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content